BioAge Labs Inc. Stock Price, News & Analysis

BioArctic AB, listed as BIOA B on Nasdaq Stockholm, will release its first quarter report for January - March 2023 on April 27, 2023, at 08:00 a.m. CET.

The company will host an audiocast with teleconference at 09:30 CET on the same day, featuring CEO Gunilla Osswald and CFO Jan Mattsson. This session will include a presentation of the financial results followed by a Q&A segment.

Investors and analysts can participate via a webcast or teleconference by registering through the provided links. The presentation will be subsequently available on BioArctic's corporate website.

BioArctic AB (NASDAQ Stockholm: BIOA B) announced that its partner Eisai published a study in Neurology and Therapy detailing long-term outcomes of lecanemab, an antibody for Alzheimer's disease. The study indicates that lecanemab can delay progression of mild cognitive impairment and early Alzheimer's by 2-3 years compared to standard care, improving patients' quality of life. This analysis includes data from the Phase 3 Clarity AD trial, contrasting lecanemab treatment with standard care. Lecanemab gained accelerated FDA approval in January 2023, and Eisai is pursuing further regulatory approvals globally, including in the U.S., Japan, and Europe.

BioArctic AB (NASDAQ Stockholm: BIOA B) presented significant findings on lecanemab, an antibody for Alzheimer's disease, at the 2023 AD/PD conference. The Phase 3 Clarity AD study involving 1,795 participants confirmed the efficacy of lecanemab, achieving its primary and all key secondary endpoints with strong statistical significance. Presentations highlighted the unique mechanism of action of lecanemab, ARIA incidences, and quality of life improvements for patients and caregivers. BioArctic, partnered with Eisai, is preparing for the joint commercialization of lecanemab in the Nordic region, where BioArctic holds the rights to market the drug.

On March 31, 2023, BioArctic AB (Nasdaq Stockholm: BIOA B) announced that its partner, Eisai, published detailed analyses from the phase 2b clinical study of lecanemab for treating mild cognitive impairment and early Alzheimer's disease. The multicenter study enrolled 856 patients, showing a consistent reduction in clinical decline over 18 months and demonstrating the potential for disease modification. Lecanemab exhibited a low incidence of amyloid-related imaging abnormalities (ARIA), with manageable side effects. BioArctic retains commercialization rights for lecanemab in the Nordic region, and both companies are preparing for joint commercialization.

BioArctic's partner, Eisai, has published new research on the societal value of the anti-amyloid-beta antibody, lecanemab (LEQEMBI™), in Alzheimer's disease. This study utilized data from the Phase 3 Clarity AD trial, revealing a gain of 0.61 quality-adjusted life-years (QALYs) from a healthcare payer perspective and a reduction in costs by $6,263 per person. For the societal perspective, the QALY gain is 0.64 and costs decrease by $7,451. Lecanemab, which received accelerated FDA approval on January 18, 2023, could significantly improve quality of life and lessen the economic burden of Alzheimer's disease.